Asset Details
Do you wish to reserve the book?
Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model
Do you wish to request the book?
Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selective activator protein‐1 inhibitor T‐5224 prevents lymph node metastasis in an oral cancer model
2016
Overview
Activator protein‐1 (AP‐1) is a transcriptional factor that regulates the expression of various genes associated with tumor invasion and migration. The purpose of our study was to assess the therapeutic effects of a novel selective AP‐1 inhibitor, T‐5224, in preventing lymph node metastasis in head and neck squamous cell carcinoma (HNSCC) in an orthotopic mouse model. We assessed the effect of T‐5224 on HNSCC cell invasion, migration, proliferation, and MMP activity by carrying out an in vitro study using an invasion assay, scratch assay, WST‐8 assay, and gelatin zymography. We also observed morphological changes in HNSCC cells by time‐lapse microscopy. Furthermore, cervical lymph node metastasis was assessed using an orthotopic tumor model of human oral squamous cell carcinoma cells (HSC‐3‐M3) injected in the tongue of a BALB/c nude mouse. T‐5224 (150 mg/kg) or vehicle was given orally every day for 4 weeks. Animals were killed and assessed for lymph node metastasis by H&E staining of resected lymph nodes. T‐5224 significantly inhibited the invasion, migration, and MMP activity of HNSCC cells in a dose‐dependent manner; there was no significant influence on cell proliferation. The antimetastatic effect of T‐5224 was also confirmed in our animal study. The rate of cervical lymph node metastasis in the model was 40.0% in the T‐5224‐treated group (n = 30) versus 74.1% in the vehicle‐treated group (n = 27; P < 0.05). In conclusion, T‐5224 inhibited the invasion and migration of HNSCC cells in vitro, and prevented lymph node metastasis in head and neck cancer in an animal model.
AP‐1 inhibitor T‐5224 prevents lymph node metastasis in head and neck cancer model.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Benzophenones - administration & dosage
/ Benzophenones - pharmacology
/ Benzophenones - therapeutic use
/ Cancer
/ Cell Movement - drug effects
/ Cell Proliferation - drug effects
/ Dose-Response Relationship, Drug
/ Female
/ Gelatin
/ Humans
/ Isoxazoles - administration & dosage
/ Isoxazoles - therapeutic use
/ Lymphatic Metastasis - prevention & control
/ Mice
/ Mouth Neoplasms - drug therapy
/ Mutation
/ Neoplasm Invasiveness - prevention & control
/ Oral squamous cell carcinoma
/ Original
/ Proteins
/ Transcription Factor AP-1 - antagonists & inhibitors
/ Uterine Cervical Neoplasms - prevention & control
